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Abstract
Background: We have previously reported that CD4 T cells from some exposed uninfected (EU)
Vietnamese intravenous drug users are relatively resistant to HIV infection in vitro. Here, we further
characterized the restriction of viral replication in CD4 T cells from five EUs and assessed its persistence
in serial samples.
Results: CD4 T cells and/or PBMC sampled during a period of between 2 and 6 years were challenged
with replication-competent HIV-1 and other retroviral particles pseudotyped with envelope proteins of
various tropisms. CCR5 expression and function in resistant CD4 T cells was evaluated. The step at which
HIV-1 replication is restricted was investigated by real-time PCR quantification of HIV-1 reverse
transcripts.
We identified three patterns of durable HIV-1 restriction in EU CD4 T cells. CD4 T cells from four of the
five EU subjects were resistant to HIV-1 R5 infection. In two cases this resistance was associated with low
CCR5 surface expression, which was itself associated with heterozygous CCR5 mutations. In the other
two cases, CD4 T cells were resistant to HIV-1 R5 infection despite normal CCR5 expression and signaling
function, and normal β-chemokine secretion upon CD4 T cell activation. Instead, restriction appeared to
be due to enhanced CD4 T cell sensitivity to β-chemokines in these two subjects. In the fifth EU subject
the restriction involved post-entry steps of viral replication and affected not only HIV-1 but also other
lentiviruses. The restriction was not overcome by a high viral inoculum, suggesting that it was not mediated
by a saturable inhibitory factor.
Conclusion: Various constitutive mechanisms of CD4 T cell resistance to HIV-1 infection, affecting entry
or post-entry steps of viral replication, are associated with resistance to HIV-1 in subjects who remain
uninfected despite long-term high-risk behavior.
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Cellular susceptibility to human immunodeficiency virus
(HIV) infection in vitro varies widely among individuals
[1,2]. Both host genetic and acquired mechanisms regu-
late HIV-1 replication. HIV requires numerous host cell
factors for efficient replication [3]. The recent discovery of
several molecules endowed with antiretroviral activity in
mice and primates underlines the contribution of innate
intracellular resistance to infection by HIV and other ret-
roviruses [4]. Some of these molecules, such as the cyti-
dine deaminase APOBEC3G, have been implicated in the
restriction of HIV-1 replication in resting human T cells
[5,6]. Resistance to HIV-1 infection in vivo has not so far
been linked to the expression or genetic polymorphism of
these restriction factors [7,8], but the efficiency of viral
replication is likely to be determined in large part by the
balance between required factors and restrictive factors.
Some individuals who are highly exposed to HIV-1 and
yet remain uninfected (exposed uninfected individuals,
EU) are likely to be naturally resistant to infection. Rela-
tive resistance of CD4 T cells and/or macrophages to HIV-
1 infection has been reported in selected EUs [9-11]. This
resistance was usually restricted to HIV-1 isolates using
the CCR5 chemokine receptor (R5 isolates) to enter target
cells [12-14]. Invalidating mutations in the CCR5 gene
confer resistance to HIV-1 R5 infection in vitro [15,16],
and the CCR5∆32 homozygous genotype is associated
with protection against HIV-1 acquisition in Caucasians
[17]. Reduced in vitro susceptibility to HIV-1 R5 of EU
CD4 T cells bearing wild-type CCR5 has been linked to
low CCR5 expression on the target cell surface and/or to
increased secretion of natural CCR5 ligands – the β-chem-
okines RANTES/CCL5, MIP-1α/CCL3 and MIP-1β/CCL4
[12] – by CD4 or CD8 T lymphocytes [18-20]. Infection of
CD4 T cells may also be inhibited by unidentified soluble
antiviral factors secreted by CD8 T lymphocytes [21]. Nev-
ertheless, CD8 T cell associated resistance to HIV-1 infec-
tion was reported to wane in EUs who reduced their high-
risk behavior, suggesting that reduced exposure led to
decreased CD8 T cell antiviral immunity [22,23].
We have previously shown that some Vietnamese intrave-
nous drug users who remained uninfected by HIV despite
more than 15 years of drug use (resulting in a high preva-
lence of other blood-borne viral infections) have low CD4
T cell permissiveness to HIV infection in vitro [11]. In
order to identify the mechanisms of CD4 T cell resistance
in this population, we investigated the characteristics of
HIV-1 restriction in five Vietnamese EUs who were moni-
tored for between 2 and 6 years. We identified three differ-
ent patterns of restriction, affecting viral entry or post-
entry steps. We also found that CD4 T cell resistance to
HIV was stable over time.
Results
CD4 T cell resistance to single-round HIV-1 infection in 
Vietnamese EUs
In a previous study of Vietnamese IDU EUs we identified
some individuals whose CD4 T lymphocytes showed
reduced susceptibility to in vitro infection by replicative
strains of HIV-1 [11]. HIV-1 replication in CD4 T cells
from three EUs (W276, W278 and B195) was far less effi-
cient than in CD4 T cells from healthy controls. Analysis
of the CCR5 gene in the same population revealed heter-
ozygous mutations in some subjects [24,25]. In two cases
(B184 and W336) the mutations in CCR5 were associated
with reduced co-receptor function in transfected cell lines
[24,26], but the effect of these mutations in heterozygous
primary cells was not assessed.
CD4 T cells from the five EUs studied here (W276, W278,
B195, B184 and W336; Table 1) had reduced susceptibil-
ity to infectious strains of HIV-1 (data not shown and
[11]; see Materials and Methods for corresponding sub-
jects designations). We used single-round infection with
envelope-pseudotyped HIV-1 NL4.3∆ env particles bear-
ing the luciferase reporter gene to investigate whether the
reduced HIV-1 susceptibility of the EUs' CD4 T cells was
detectable during the first cycle of viral replication (fig. 1).
In four out of five cases (W278, B195, B184, W336), CD4
T cells were less susceptible to infection by a CCR5-tropic
(R5) HIV-1 pseudotype (HIV-BaL), while they were per-
missive to infection by a CXCR4-tropic (X4) HIV-1 pseu-
dotype (HIV-HxB2) and to HIV-1 particles pseudotyped
with the G protein from vesicular stomatitis virus (HIV-
VSVG), which has a ubiquitous (pantropic) receptor and
uses an endocytic entry pathway [27] (fig. 1). These results
showed that the CD4 T cells of the EUs with heterozygous
mutations in CCR5 (B184 and W336) were less suscepti-
ble to infection by HIV-1 R5 pseudotype and confirmed
our previous observation that HIV-1 restriction in subjects
W278 and B195 is specific to R5 viruses [11]. As shown,
single-round infection of CD4 T cell from these four EUs
was partially reduced. Interestingly, when replication-
competent HIV-1 strains were used, inhibition of infec-
tion was much stronger (data not shown and [11]), sug-
gesting that the restrictions observed during the first
round of HIV-1 replication are amplified during subse-
quent cycles.
Remarkably, CD4 T cells from subject W276 were resistant
to both R5 and X4 HIV-1 pseudotypes and also to the HIV-
VSVG pseudotype. These results indicated that the restric-
tion was independent not only of HIV coreceptors, as pre-
viously shown [11], but also of the entry pathway used by
the virus (fig. 1).Page 2 of 12
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Reduced susceptibility of EU CD4 T cells to infection by pseudotyped HIV-1Fig r  1
Reduced susceptibility of EU CD4 T cells to infection by pseudotyped HIV-1. CD4 T cells were challenged with HIV-
1 particles pseudotyped with R5 (BaL) (white bars), X4 (HxB2) (black bars) or pantropic (VSV-G) (patterned bars) envelope 
glycoproteins. Results (mean of three experiments) are expressed as relative luciferase activity in cell lysates three days after 
infection. Luciferase activity in cell lysates from a representative control was attributed a value of 100%. Error bars represent-
ing standard deviation are shown in each case.
Table 1: Characteristics of the study subjects.
EU code Year of birth Sex IDU started Risk ended Serology Enrollment Follow-up ended
HBc HBs HCV HTLV Year Year
W276 1960 M 1979 2003 + - + + 1996 2004
W278 1955 M 1978 2000 - - + + 1996 2004
W336 1958 M 1975 2001 + - + + 1996 2004
B184 1951 M 1972 2003 + - + + 1998 2004
B195 1949 F 1972 Unknown + - + - 1998 1999
HBc: anti-hepatitis B virus antibodies; HBs: hepatitis B antigen; HCV: hepatitis C virus; HTLV: human T cell leukaemia/lymphoma virus (I and/or II)
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As already mentioned, CCR5 heterozygous mutations had
been detected in subjects B184 and W336 (G106R and
C178R respectively) [24,25]. These (or equivalent) muta-
tions, when present in the homozygous state in trans-
fected cell lines, affect the receptor conformation and
both CCR5 membrane trafficking and function [24,26].
However, CCR5 surface expression by these two EUs' pri-
mary CD4 T cells has not been evaluated before.
Flow cytometry of R5-restricted CD4 T cells revealed that
the percentage of CD4 T cells expressing detectable surface
CCR5 was far lower in the two EUs carrying heterozygous
CCR5 mutations (B184 and W336) than in controls
expressing the wild-type (wt) CCR5 molecule (fig. 2A). In
contrast, no such difference was found, in either the per-
centage (fig. 2A) or the mean fluorescence intensity (MFI),
in the other two EUs (W278 and B195) who both had wt
CCR5 (the CCR5 MFI was 1.38 and 1.21 in subjects W278
and B195, respectively, and 1.39 ± 0.24, mean ± SD, in
five CCR5-wt controls).
Therefore, the low surface expression of CCR5 on CD4 T
cells from EUs B184 and W336 is likely linked to CCR5
mutations and appears to affect R5 virus entry into target
cells. However, HIV R5 replication in CD4 T cells from
subjects W278 and B195 was restricted despite normal
CCR5 surface expression (fig. 2A). We therefore examined
whether CCR5 function was impaired in the CD4 T cells
of these two subjects, affecting signaling events potentially
involved in HIV-1 replication [28,29].
As actin cytoskeleton reorganization is a major character-
istic of chemokine responses, we analyzed CCR5-medi-
ated actin polymerization in CD4 T cells from subjects
W278 and B195. RANTES stimulation of CD4 T cells
induced a rapid increase in the F-actin content of cells
from the two EUs and from four CCR5-wt controls (fig.
2B). The peak responses occurred 15–30 s after stimula-
tion, in keeping with a fully functional chemoreceptor
[30]. Cell pretreatment with the CCR5 inhibitor TAK-779
[31] abrogated actin polymerization.
The restriction in CD4 T cells from subjects W278 and
B195 affected HIV-1 viruses pseudotyped with different
R5 tropic envelopes (JRFL [32] and YU2 [33]) (fig. 2C).
These results confirmed that the restriction in W278 and
B195 CD4 T cells is specific for the CCR5 entry pathway
and indicated that it is independent of CCR5 expression
and function.
Abrogation of viral restriction in cells from subjects W278 
and B195 with anti-β-chemokines
R5 virus entry into CD4 T cells can be blocked by endog-
enously produced β-chemokines [20]. We therefore inves-
tigated whether the restriction of HIV-1 R5 replication in
CD4 T cells from subjects W278 and B195 could be over-
come by neutralizing monoclonal antibodies (MAbs) to
RANTES, MIP1α and MIP1β. The addition of anti-β-
chemokine mAbs, but not of irrelevant IgGs, strongly
enhanced the infection of both W278 and B195 cells by
the HIV-1 pseudotype, while no significant enhancement
was observed in CCR5-wt control cells with similar CCR5
surface expression (fig. 3A). These results suggest that
endogenously produced β-chemokines may be responsi-
ble for the inhibition of HIV-1 infection in CD4 T cells
from subjects W278 and B195.
When we challenged CD4 T cells with BaL pseudotyped
HIV in a setting of weak β-chemokine production (before
PHA and IL2 activation; <3 ng) we found that infection
was as efficient in the two EUs as in controls (fig. 3B). This
was consistent with the hypothesis that the inhibition of
HIV-1 infection in PHA-activated CD4 T cells from sub-
jects W278 and B195 involved chemokines produced
upon cell activation. However, quantification of β-chem-
okines produced by PHA-activated CD4 T cells at the time
of HIV-1 infection (three days after PHA stimulation)
showed no significant increase in β-chemokine secretion
in W278 and B195 cell cultures compared to controls
(Table 2).
To investigate the possibility of enhanced sensitivity to β-
chemokines, we infected non-stimulated CD4 T cells from
subject B195 (not enough cells from subject W278 were
available) in the presence of a cocktail of recombinant
RANTES, MIP1α and MIP1β added at increasing concen-
trations. In the presence of low levels (≤ 5 ng) of recom-
binant β-chemokines, HIV-1 replication was comparable
in B195 and CCR5-wt control CD4 T cells (Fig. 3C), as
already observed in the absence of added β-chemokines
(Fig. 3B). In contrast, when the β-chemokine levels were
increased, the efficiency of infection fell sharply in B195
CD4 T cells and far less markedly in control CD4 T cells
(fig. 3C) (ID50 values were 8.12 ± 1.58 ng/ml and 59.34 ±
16.87 ng/ml for B195 and control respectively). CD4 T
cell CCR5 surface expression was similar in the two indi-
viduals (data not shown). These results indicated that HIV
infection of CD4 T cells from EU subject B195 was unusu-
ally susceptible to inhibition by β-chemokines.
Pantropic restriction of HIV replication in subject W276 
affects several lentiviruses
The blockade of in vitro HIV infection in CD4 T cells from
subject W276 was independent of viral tropism and of the
entry pathway (fusion or endocytosis) (fig. 1). In a fluori-
metric fusion assay with cells expressing HIV-1 envelope
proteins [34], W276 CD4 T cells showed normal mem-
brane fusion (not shown), further supporting post-entry
restriction of viral replication in these cells.Page 4 of 12
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R5 tropic HIV-1 restriction in CD4 T cells from four EUsFigure 2
R5 tropic HIV-1 restriction in CD4 T cells from four EUs. A. Relative infection by the HIV-BaL pseudotype (white bars; 
n = 3, mean ± SD) of CD4 T cells from the EUs B184, W336, B195 and W278, and percentage of cells with detectable surface 
expression of the CCR5 co-receptor (black bars, one experiment shown, representative of two different experiments). B. 
CCR5-mediated actin polymerisation in CD4 T cells from W278 () B195 (▼) (top left and right panels respectively) and four 
different CCR5-wt controls. Cells from a control donor (bottom right panel) were also treated with TAK-779 (2 µM) for 60 
minutes before RANTES stimulation (open circles). Results show the kinetics of actin polymerization triggered by RANTES 
stimulation, as measured by the incorporation of the FITC-phalloidin probe. The percentage of actin polymerization is 
expressed as follows: [(MFI after ligand addition)/(MFI before ligand addition)] × 100. 100% corresponds to the baseline level of 
unstimulated cells. C. Relative infection of CD4 T cells from subjects W278 (white bars) and B195 (black bars) by R5 (HIV-BaL; 
HIV-JRFL; HIV-YU2), X4 (HIV-HxB2) and pantropic (HIV-VSVG) pseudotypes (n = 3, mean ± SD). The luciferase activity in cell 
lysates from one representative control was attributed a value of 100%.
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Role of β-chemokines in HIV-1 restriction in CD4 T cells from subjects W278 and B195Figure 3
Role of β-chemokines in HIV-1 restriction in CD4 T cells from subjects W278 and B195. A. CD4 T cells from sub-
jects W278 and B195 were challenged with the HIV-BaL pseudotype in the absence (white bars) or presence of a combination 
of neutralizing anti-RANTES (5 µg/ml), anti-MIP1α (15 µg/ml) and anti-MIP1β (25 µg/ml) (R&D systems, France) mAbs (black 
bars) or with an isotype control antibody (45 µg/ml) (patterned bars). The antibodies were added 30 minutes before challenge 
and maintained throughout the time course of infection. Results are expressed as relative luciferase activity, compared to the 
maximal activity found in the presence of the neutralizing anti-β-chemokines in each case, and are the mean of three independ-
ent infections ± standard deviation. ** Significant difference (P < 0.001 and P = 0.008 for W278 and B195, respectively, inde-
pendent sample t-test). B. Challenge with the HIV-BaL pseudotype (n = 3, mean ± SD) of CD4 T cells from EUs W278 and 
B195, stimulated with PHA three days before (white bars) or two hours after (black bars) challenge. Luciferase activity in cell 
lysates from a representative control challenged in the same conditions was attributed a value of 100%. C. Sensitivity of CD4 T 
cells to recombinant chemokines. Non mitogen-stimulated CD4 T cells from EU B195 (filled circles) and one control (open 
squares) were exposed to various concentrations of a mixture of the recombinant β-chemokines RANTES, MIP-1α and MIP-1β 
(R&D systems, France) for 30 minutes prior to and during infection. The mixtures contained the three chemokines at concen-
trations ranging from 500 ng to 2 ng each. Results (n = 3, mean ± SD) are expressed as luciferase activity per second in cell 
lysates. Points were fitted to a four-parameter logistic curve (r2 were 0.845 and 0.826 for B195 and control, respectively). Sta-
tistical analysis and curve-fitting were performed with Sigmaplot software (Systat Software, Inc, CA, USA).
Retrovirology 2006, 3:81 http://www.retrovirology.com/content/3/1/81Previous qualitative PCR analysis of viral replication in
CD4 T cells from subject W276 suggested that the restric-
tion step occurred before integration [11], but early times
post-infection were not analyzed. We therefore used sin-
gle-round infection and real-time PCR to determine the
precise stage at which the restriction occurred. Early
reverse transcription products (R-U5) were far lower in
W276 cells than in control cells, from the very first hours
after infection (fig. 4A), and they increased very little dur-
ing the time course of infection. Levels of PCR products
corresponding to subsequent replication steps were also
decreased (not shown). These results suggest that early
post-entry steps of viral replication, most likely involving
reverse transcription, are impaired in W276 CD4 T cells.
Note that W276 CD4 T cells were readily activated by PHA
(>95% of cells were CD25+ at the time of challenge) thus
discarding that the restriction of HIV-1 infection was
caused by a defect of the response to PHA-stimulation. In
addition, HIV-1 restriction in W276 CD4 T cells was not
overcome by increasing the size of the inoculum of VSV-G
pseudotyped HIV-1 (fig. 4B), arguing against a role of a
saturable restriction factor.
To determine whether the restriction of viral replication in
CD4 T cells from subject W276 was specific to HIV-1 or
also affected other lentiviruses, we challenged the cells
with SIVagm and SIVmac luciferase reporter viruses (fig.
4C) pseudotyped with VSV-G. Replication of both viruses
was strongly inhibited in W276 CD4 T cells.
Persistence of HIV-1 restriction in primary cells from 
Vietnamese EUs
To determine whether resistance to infection was transient
or persistent, we tested primary CD4 T cells or PBMC
obtained from the five EUs at various times during 2–6
years of follow-up. The samples included cells obtained
from four of the subjects (W276, W278, W336 and B184)
after alleged interruption of IV drug use (Table 3). In
infectivity assays with PHA-activated cells, HIV-1 replica-
tion was always inhibited in the EU cells compared to
control cells. Moreover, the same pattern of HIV-1 inhibi-
tion (R5-restricted or tropism-independent) was observed
in serial samples from each EU (not shown), confirming
the persistence of individual restriction phenotypes.
Discussion
We have previously reported that CD4 T cells from some
Vietnamese individuals who remain free of infection after
several years of intravenous drug use show reduced sus-
ceptibility to HIV-1 infection [11]. Here we extended our
investigations of the mechanisms underlying HIV-1
restriction in CD4 T cells and found that both entry and
post-entry steps of HIV-1 replication could be affected.
Interestingly, the restriction in one of these subjects also
affected other lentiviruses. In addition, the restriction
mechanisms persisted for several years.
The same patterns of in vitro CD4 T cell resistance to HIV-
1 infection were observed after alleged interruption of at-
risk behaviors, suggesting that the mechanisms of resist-
ance in these subjects do not depend on exposure to the
virus but rather might be linked to constitutive factors. It
is noteworthy in this respect that heterozygous CCR5
mutations in two of the five EUs studied here (B184 and
W336) were associated with low CCR5 surface expression
on their primary CD4 T cells and with resistance of these
cells to HIV-1 R5 infection. CCR5∆32 heterozygosity has
been associated with decreases both in CCR5 surface
expression and in susceptibility to in vitro infection by R5
viruses, although to a lesser extent than CCR5∆32
homozygosity [35-37]. Low CCR5 expression in
CCR5∆32 heterozygous cells has been attributed to sev-
eral mechanisms, including sequestration of the wild-type
molecule by the mutant molecule in the endoplasmic
reticulum, and reduced gene dosage [37-39]. The molecu-
lar mechanisms underlying the reduced CCR5 expression
in the heterozygous Vietnamese EUs' CD4 T cells are
under investigation.
CD4 T cells from subjects W278 and B195 were also resist-
ant to infection by HIV-1 R5, even though these EUs had
the wild-type CCR5 molecule. HIV restriction in these
subjects' cells was abrogated by anti-β-chemokine Abs.
Accordingly, PCR experiments suggested that the block in
CD4 T cells from subjects W278 and B195 affected very
early steps of viral replication [11], likely reflecting inhibi-
tion of viral entry by β-chemokine ligands of CCR5 [40].
Partial resistance to HIV-1 R5 in cells from some CCR5-wt
EUs has previously been linked to decreased CCR5 expres-
Table 2: β-chemokines produced by mitogen-activated CD4 T cells.
EU code RANTES (ng/ml) MIP1α (ng/ml) MIP1β (ng/ml)
W278 33.7 26.4 39.1
B195 19.7 56.3 66.8
Controlsa 14.1 (11.7–34.3) 30.6 (26.8–49.8) 58.3 (45.5–67.3)
a median and range for the 5 controls used in the experiments shown in figures 2 and 3.Page 7 of 12
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Pantropic restriction in CD4 T cells from subject W276 affects the replication of several retrovirusesFigure 4
Pantropic restriction in CD4 T cells from subject W276 affects the replication of several retroviruses. A. Early 
reverse transcripts (RU5) analyzed by real-time PCR at various times after HIV-VSVG pseudotype challenge of CD4 T cells 
from subject W276 (open circles) and a representative control (filled triangles). B. Infection of CD4 T cells from subject W276 
(open circles) and a control (filled triangles) with increasing amounts of HIV-VSVG pseudotype. Results (mean of three inde-
pendent infections) are expressed as luciferase activity per second in cell lysates three days post-challenge. The control is rep-
resentative of cells from three different controls. Error bars represent the standard deviation. C. Relative infection of CD4 T 
cells from subject W276 (white bars) by HIV-1, SIVmac and SIVagm particles pseudotyped with the VSVG fusion protein (n = 3, 
mean ± SD). Luciferase activity in cell lysates from a representative control (black bars) was attributed a value of 100%.
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ine secretion [12]. CCR5 expression on CD4 T cells from
subjects W278 and B195 was not subnormal. However, as
CCR5 expression on thawed cells (including from con-
trols) was too low for FACS analysis, our experiments
were done 10 days after PHA stimulation and we cannot
therefore formally exclude the possibility that CCR5
expression was reduced on W278 and B195 CD4 T cells at
the time of infection (three days after PHA stimulation)
and recovered rapidly thereafter. Nevertheless, β-chemok-
ine secretion by CD4 T cells upon mitogen activation was
not higher in the two EUs than in controls, suggesting that
the inhibitory mechanism differs from those previously
reported. Moreover, non-stimulated CD4 T cells from
these two EUs expressed normal levels of CCR5 and
allowed HIV-1 entry and replication. However, in these
conditions, in which endogenous secretion of β-chemok-
ines is very low, HIV-1 infection was inhibited by exoge-
nous β-chemokines at lower concentrations than in
experiments with control cells. Thus, HIV-1 inhibition in
PHA-activated CD4 T cells appears to result from
enhanced sensitivity to secreted β-chemokines. In the con-
text of wild-type CCR5, this increased sensitivity might be
governed by the chemoreceptor microenvironment,
which has been shown to influence both CCR5 affinity for
its agonists [41] and β-chemokine-induced CCR5 inter-
nalization [42].
CD4 T cells from subject W276 exhibited a pantropic
restriction phenotype independent of the virus entry path-
way. Viral replication was blocked at early post-entry
steps, probably through impaired reverse transcription.
The restriction pattern in W276 cells (i.e. non-saturable,
blockade of several lentiviruses) differed from that attrib-
uted to TRIM5α and APOBEC family proteins – restriction
factors that also target early post-entry steps of viral repli-
cation [43-45]. Preliminary analyses of heterokaryons
obtained by fusion of W276 CD4 T cells with the HIV-sus-
ceptible cell line A2.01 (data not shown) suggest that the
restriction in EU W276 cells might be due to missing or
defective cell factor(s) necessary for viral replication,
rather than to antiviral molecules.
Strong CD4 T cell resistance to HIV-1 infection is a highly
unusual phenomenon and it is reportedly more frequent
among EUs [9,11]. These cells provide unique opportuni-
ties for identifying novel HIV-1 resistance mechanisms.
For example, the CCR5∆32 homozygous genotype was
first identified in two EUs with reduced susceptibility to
HIV-1 infection [15], but has since been associated with
protection in Caucasians [17] and has led to the develop-
ment of CCR5-targeting drugs [46]. However, CCR5∆32
homozygosity accounts for cell resistance in only a small
fraction of Caucasian EUs.
Conclusion
Each of the in vitro resistance mechanisms described here
may contribute to protection against HIV-1 infection in
exposed uninfected Vietnamese individuals, possibly in
conjunction with other innate or adaptive antiviral
responses [47,48]. Low CCR5 expression due to CCR5
mutations in target cells may limit the infection and
spread of HIV-1 R5 viruses, which are preferentially trans-
mitted and predominate in the early phases of the human
infection [49,50]. β-chemokine-mediated resistance to
HIV-1 R5 infection of activated CCR5-wt CD4 T cells
could limit HIV-1 transmission and spread at preferential
sites of viral replication. Indeed, HIV-1 replication occurs
mainly in activated CD4 T cells, which tend to be located
in β-chemokine-rich environments such as lymph nodes
and gut-associated lymphoid tissue [51,52]. Finally, near-
complete restriction of viral replication, as found in the
cells of EU subject W276, probably protects against HIV-1
transmission, as in CCR5∆32 homozygous individuals.
Identification of the mechanisms and molecules involved
in such broad lentivirus restriction may lead to new viral
and/or cellular targets for anti-HIV therapy.
Materials and methods
Study subjects
The five EUs studied here (Table 1) belonged to a popula-
tion of intravenous drug users (IDU) who had been
exposed to HIV-1 through needle sharing for many years
[11,53]. Subjects W276, W278, and B195 correspond to
subjects EU1 to EU3 and subject B184 corresponds to sub-
Table 3: Restriction in infectivity assays.
EU code PBMC samples tested for HIV-1 infectivitya CD4 cell samples tested for HIV-1 infectivitya Restricted tropismb
Year (month) Year (month)
W276 1999 (1, 7) 1998 (1), 1999 (1, 7), 2004 (6) Pantropic
W278 1998 (1), 2000 (4) 1998 (1), 2000 (4, 8), 2004 (6) R5 tropic
W336 1998 (1) 1998 (1), 2001 (1, 4) R5 tropic
B184 1998 (11) 1998 (1, 11), 2004 (1) R5 tropic
B195 1998 (1), 1999 (1) 1998 (11), 1999 (1, 7) R5 tropic
a Cell samples tested for HIV-1 susceptibility in single-round or productive infection. b Tropism associated with HIV-1 restriction (see figure 1).Page 9 of 12
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recruited, they had been using drugs for 17 to 26 years. All
continued high-risk practices for several years despite
medical counseling. Four subsequently said they had
stopped at-risk drug use between 2000 and 2003 (Table
1). Subject B195 was lost to follow-up in July 1999. Con-
trols were Vietnamese (20) and European (7) healthy
blood donors with a low risk of HIV-1 infection (Red
Cross, Vietnam and Centre de Transfusion Sanguine Ile-
de-France, Rungis, France). All the infectivity assays with
EU CD4 T cells were performed in parallel with suscepti-
ble CD4 T cells from at least three randomly selected con-
trols. All participants gave their informed consent.
CD4 T cells
Peripheral blood mononuclear cells (PBMC) from EUs
and controls were isolated from whole blood by Ficoll-
Hypaque centrifugation. CD4 cells were purified from
thawed PBMC by positive selection with antibody-coated
immunomagnetic beads (Miltenyi Biotech, France). Acti-
vated CD4 T cells (>95% CD4+CD3+CD25+ as estimated
by flow cytometry) were obtained after stimulation for
three days with phytohemagglutinin (PHA, 1 µg/ml) and
interleukin-2 (IL2) (Chiron, France, 100 IU/ml) and were
maintained in RPMI 1640 medium containing 10% fetal
calf serum, penicillin/streptomycin (100 U/ml) and IL2.
Production of reporter viral particles and infectious 
challenge
Pseudotyped reporter retroviral particles were produced
by transiently co-transfecting 293T cells with the proviral
constructs pNL-Luc-E-R+, pSIVmac-Luc-E-R+ or pSIVagm-
Luc-E-R+ [43,54] and the VSV-G, HxB2-Env, BaL-Env,
JRFL-Env or YU2-Env expression vectors (7.5 µg each)
using the lipofection reagent SuperFect (Qiagen, France).
Supernatants were harvested 48 h after transfection, and
105 CD4 T cells were infected (m.o.i: 0.1–1.0) in triplicate
in 96-well plates with a spinoculation protocol [55] (1
hour of centrifugation at room temperature at 1500 g, fol-
lowed by 1 hour at 37°C). After challenge, cells were
extensively washed and then cultured.
Quantification of luciferase activity in cell lysates
Three days after challenge the cells were harvested and
lysed with 100 µl of luciferase lysis buffer (Promega,
France). Luciferase activity was quantified in 10 µl of each
lysate with the Promega Luciferase Assay System in a Ver-
itas microplate luminometer (Turner BioSystems, CA,
USA).
CCR5 genotypic characterization
DNA was extracted from PBMC with the DNeasy Tissue
Kit (Qiagen, Courtaboeuf, France). The full-length coding
region (exon 4) of the CCR5 gene was amplified with
primers and in conditions described elsewhere [24].
PCR products were purified with the ExoSAP-IT® enzyme
for PCR Product Clean-Up (Pharmacia-Amersham, USA)
and were directly sequenced with the BigDye Terminator
cycle sequencing kit (ver.3.1; Applera, France). Sequences
were determined with an automatic sequencer (ABI-Prism
3100, Applied Biosystem, USA) and analyzed with SeqS-
cape software version 2.5 (Applied Biosystem, USA).
Flow cytometry of CCR5 expression
Ten days after PHA activation, CD4 T cells were incubated
for 30 minutes at room temperature with CCR5-FITC
(clone 2D7) (BD Bioscience, France) and analyzed on a
Cytomics FC500 flow cytometer (Beckman Coulter, Paris,
France).
CCR5-mediated actin polymerisation
Actin polymerization in CD4 T cells was measured as
described elsewhere [30]. Briefly, ten days after PHA stim-
ulation, cells (1 × 107 cells/mL) were incubated in RPMI
medium containing 20 mM HEPES in the presence or
absence of inhibitor. RANTES (30 nM) was then added to
the cell suspension. At each indicated time point (15 s to
2 min), a 50-µL aliquot of cell suspension was mixed with
200 µL of labeling buffer consisting of 10-7 M FITC-phal-
loidin (Sigma), 0.125 mg/mL L-α-lysophosphatidylcho-
line palmitoyl (Sigma) and 4.5% PFA in PBS. The kinetics
of actin polymerization was monitored by means of flow
cytometry. Results are expressed as follows: [MFI after
addition of ligand/MFI before addition of ligand] × 100].
MFI values before ligand addition were arbitrarily set at
100%. Owing to the large number of cells required, CD4
T cells were amplified on irradiated heterologous feeder
PBMC for two weeks prior to testing. The pattern of HIV-
1 restriction in amplified cells was similar to that found in
the primary CD4 T cells (not shown). TAK-779 was
obtained through the NIH AIDS Research and Reference
Reagent Program, Division of AIDS, NIAID, NIH.
Quantification of secreted β-chemokines
Levels of β-chemokines, RANTES, MIP-1α and MIP-1β in
the supernatants of CD4 T cells were measured after 72 h
of culture with or without PHA stimulation, by using
commercial ELISA kits (Quantikine, R&D systems,
France).
Real-time PCR quantification of HIV-1 replication 
intermediates
Three days after PHA stimulation, CD4 T cells were chal-
lenged with DNase (Invitrogen, France)-pretreated viruses
(1 h at room temperature). At the times indicated, 5 × 105
cells were washed in PBS and lysed, then total DNA was
extracted with the DNeasy Tissue Kit (Qiagen, France).
Early HIV-1 reverse transcription products were quantified
with an ABI PRISM 7000 instrument (Applied Biosystems,
France) using specific primers and probe as previouslyPage 10 of 12
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Retrovirology 2006, 3:81 http://www.retrovirology.com/content/3/1/81described [56]. One hundred nanograms of template
DNA was used per reaction, and the albumin gene was
used as a housekeeping gene to normalize sample input.
8E5 cells containing one integrated copy of HIV-1 per cell
[57] were used to construct standard curves.
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